# Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

> **NCT01096667** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 194 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hypertension

## Interventions

- **DRUG:** Placebo to Ertuglilflozin 1 or 5 mg
- **DRUG:** Ertugliflozin 1 mg
- **DRUG:** Ertugliflozin 5 mg
- **DRUG:** Ertugliflozin 25 mg
- **DRUG:** HCTZ 12.5mg
- **DRUG:** Placebo to HCTZ
- **DRUG:** Placebo to ertuglilflozin 25 mg

## Key facts

- **NCT ID:** NCT01096667
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-17
- **Primary completion:** 2011-02-09
- **Final completion:** 2011-02-25
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2018-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01096667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01096667, "Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01096667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*